We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Animalcare Group Plc | LSE:ANCR | London | Ordinary Share | GB0032350695 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 210.00 | 204.00 | 216.00 | 210.00 | 210.00 | 210.00 | 4,247 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Veterinary Service-livestock | 71.62M | 1.97M | 0.0327 | 64.22 | 126.21M |
TIDMANCR
RNS Number : 3709A
Animalcare Group PLC
29 September 2020
Animalcare Group plc
Interim Results for the six months ended 30 June 2020
29 September 2020. Animalcare Group plc ("the Company" or "Group") (AIM: ANCR), the international animal health business, announces its unaudited interim results for the six months ended 30 June 2020.
The Group is pleased to report a resilient first half performance and remains well-placed to navigate the challenges due to COVID-19. We entered 2020 in a strong financial position and this has been maintained throughout the period, important both in terms of the Group's operational resilience and its ability to focus on the execution of our growth strategy.
Financial Highlights
-- Resilient financial performance at higher end of the Board's range of pandemic scenario modelling
-- Revenue GBP34.5m (2019: GBP36.1m), a decline of 4.4% (4.8% at CER) compared to prior year period due to COVID-19. Production Animals sales increased by 13.1%, partially offsetting the negative impact of government pandemic controls on the Companion Animals sector
-- Underlying* EBITDA down 2.4% on the prior year, reflecting cost efficiencies generated in 2019 and decisive realignment of SG&A spend during Q2 2020
-- Cash conversion rate of 56.9% (2019: 92.3%) for first half as a result of COVID-19 disruption and previously announced strategic stock build in relation to manufacturing transfers
-- Net debt GBP18.1m as of 30 June 2020 (GBP17.8m at 1 January 2020), adversely impacted by currency variations
-- Underlying* basic EPS 5.9 pence (6.4 pence for first half 2019)
-- Declared interim dividend of 2.0 pence per share, in line with prior period. Funds initially allocated for 2019 final dividend retained for investment in growth opportunities
*The Group presents a number of non-GAAP Alternative Performance Measures (APMs) which exclude non-underlying items as set out in note 3. EBITDA is defined as underlying earnings before interest, tax, depreciation and amortisation.
Strategic and Operational Highlights (including post-period)
Despite disruption to Animalcare's markets caused by the COVID-19 pandemic, the Group has maintained a strong focus on delivery of its long-term growth strategy.
Business development
-- Post-period end, Animalcare signs CA$5 million agreement with Kane Biotech to form an animal health company to target biofilm-related ailments. The Group will commercialise Kane Biotech's range of oral care products for companion animals outside the Americas while the jointly-owned company will focus on research and development of novel animal treatments based on biofilm targeting technology.
-- The roll-out of Procanicare, the probiotic gastrointestinal treatment for dogs, progresses across markets despite disruption to operation of veterinary practices caused by COVID-19.
Pipeline
-- Animalcare's novel COX-2 inhibitor pain treatment continues to progress through the regulatory process. Planned 2021 launch subject to approval.
Operational Highlights
-- Sales and marketing excellence programme initiated to optimise launch and commercialisation of differentiated products.
-- Review of operations to capitalise on the accelerated transition to digital working by veterinary practices, suppliers, distributors and other stakeholders.
Animalcare's Chief Executive Officer, Jenny Winter, commented: "Animalcare has shown exceptional resilience in the face of unprecedented conditions caused by the pandemic. Our performance across the Group was at the upper end of the range of our scenario modelling, highlighting the strength of our financial position as well as the agility, commitment and deep market knowledge of our people.
"While trading to the end of August was broadly in line with the same period last year, uncertainty about the economic and market impact of the pandemic prevails. However, the attractive fundamentals of the animal health sector, the steady recovery in our markets as veterinary practices adapt to life with COVID-19, combined with the impressive response of the Group to these difficult conditions and our maturing pipeline underpin our confidence in the future and further strengthen our long-term focus on growth.
"Notably, our continuing pursuit of value-creating growth opportunities resulted in the recently announced agreement with Kane Biotech centred on the treatment of biofilm-related ailments in companion animals. This is a significant deal that complements our existing portfolio and is an example of our focus on developing long-term sustainable commercial relationships."
Analyst briefing
A briefing for analysts will be held at 10:30 BST on Tuesday 29 September via teleconference. Analysts wishing to join should contact InvestorRelations@panmure.com to register and receive dial-in details. A copy of the analyst presentation will be made available on the Group website shortly after the analyst briefing .
For further information please contact:
Animalcare Group plc Panmure Gordon (Nominated Adviser Tel: +44 (0)1904 487 687 & Broker) Jenny Winter, Chief Executive Officer Tel: +44 (0)20 7886 2500 Chris Brewster, Chief Financial Officer Corporate Finance Media relations Freddy Crossley / Emma Earl communications@animalcaregroup.com Corporate Broking Rupert Dearden
About Animalcare www.animalcaregroup.com
Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 32 countries in Europe and a further 16 worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
Chairman's Statement
Animalcare has demonstrated remarkable resilience and strategic focus during what has been an extraordinarily testing period for our sector.
That resilience is underlined by our financial performance over the first half of 2020. To have navigated such challenging trading conditions with a year-on-year decline in revenue and Underlying EBITDA of 4.4% and 2.4% respectively - at the higher end of our scenario modelling range - is testament to the agility of our business and the strength of the platform we had built coming into 2020. You can read more details about our performance in the Financial Review of this report.
This platform not only allows us to deal with the economic reverses, the cash it generates equips us to grow our business. Under our CEO Jenny Winter, the Group has succeeded in keeping our long-term growth strategy in sharp focus despite the disruption of COVID-19. The strengthened capability of our leadership team has enabled us to continue pursuing investment opportunities that will grow our business and create sustainable value for our shareholders. Our recently announced agreement with Canada's Kane Biotech is an excellent example of this approach and the Board is open to use the full range of appropriate funding options as we deliver on our business development objectives in the coming months and years.
The Group's internal pipeline has also reached an important phase with our differentiated COX-2 inhibitor pain treatment progressing in line with our expectations. We believe this novel drug has significant potential in all our markets. To maximise that opportunity, we have developed detailed plans to support a 2021 launch - regulatory approval permitting, of course.
There are many reasons to be optimistic as we execute our growth strategy. But while the worst of the pandemic may be behind us, the spread of the COVID-19 virus and its economic aftereffects create continued uncertainty.
In March this year the Board decided to defer payment of the second dividend for 2019, providing a platform to continue progressing opportunities during the pandemic crisis. In keeping with our undertaking at the time, we have now reviewed this deferral and have decided to retain the GBP1.4m initially allocated for the second 2019 dividend to support investment in growth. A proportion of these funds will now be directed to support the agreement with Kane Biotech. Reflecting the resilience of the business over the first half and post period end, as well as the confidence of the Board, we propose to resume payment of the dividend for 2020. We strongly believe that this approach is in the long-term interests of shareholders.
Our Company is in a strong position as a direct result of the hard work, expertise and market knowledge of our people across the organisation. I'd like to take this opportunity to thank our employees who have shown exceptional commitment during these unprecedented times.
Jan Boone, Chairman
Business Review
We continue to make progress on our five clear strategic priorities that are designed to deliver our goal of above market growth in three to five years.
Strong financial platform
Entering 2020 on a strong financial platform has enabled the Group to weather the disruption and challenges caused by COVID-19 while continuing to invest in opportunities for growth. While revenues were down by 4.4% year-on-year over the first half and underlying EBITDA declined 2.4%, overall performance metrics were at the upper end of the range in the Group's scenario modelling. The benefits of the Group's diverse portfolio were visible in the growth in Production Animals (up 13.1%) partially offsetting the 10.6% decline in the Companion Animals segment which was more impacted by government measures designed to combat spread of COVID-19.
Right people and capabilities
The Group continues to strengthen the leadership team and capabilities across the organisation. The roll-out of our Sales and Marketing excellence programme is designed to improve the quality and consistency of approach. This will be particularly important in supporting the market development, launch and ongoing commercialisation of differentiated products. With the pandemic accelerating the shift to digital working by veterinary practices, suppliers, distributors and other stakeholders, the Group has initiated a review of operations in order to capitalise on the rapidly developing "new normal".
Reinforcing our existing portfolio
We continue to move towards our target of generating 80% of revenue from the top 20 products by reducing the number of low revenue products and increasing sales and marketing activities on the largest products with highest margins and biggest growth prospects. Several products have been delisted or withdrawn during the period.
Building our pipeline
Animalcare's novel COX-2 inhibitor pain treatment (Enflicoxib E-6087) continues to progress through the regulatory process. Detailed plans are in place for a concerted 2021 launch across all direct markets and through international partners, subject to approval.
Business development
The Group is pursuing a number of opportunities that will reinforce the existing portfolio, generate increased revenues from a reduced number of differentiated products and extend geographical reach.
The recently announced CA$5 million agreement with Canadian company Kane Biotech will form an animal health company to target biofilm-related ailments. Under the terms of the deal, Animalcare will commercialise Kane Biotech's range of oral care products for companion animals outside the Americas while the new jointly-owned company, named STEM Animal Health Inc., will focus on the research and development of novel animal treatments based on biofilm targeting technology. Animalcare launches of Kane Biotech's coactiv+(TM) and DispersinB(R) products are planned for the second half of 2021 and the Board expects the agreement to be earnings enhancing in 2022.
The roll-out of Procanicare, the probiotic gastrointestinal treatment for dogs, is progressing across markets despite the disruption to the operation of veterinary practices caused by COVID-19, especially in the first half.
Financial Review
Overview of underlying financial results
The Group is pleased to report a resilient first half trading performance despite the disruption due to COVID-19. We entered the financial year in a strong financial position, which has been maintained throughout the period.
A summary of the underlying financial results, which the Directors believe provides a clearer understanding of business performance, is shown below.
Six Months to 30 June 2020 2019 % Change at AER GBP'000 GBP'000 % -------- -------- --------- Revenue 34,520 36,121 (4.4%) -------- -------- --------- Gross Profit 17,937 19,135 (6.3%) -------- -------- --------- Gross Margin % 52.0% 53.0% (1.0%) -------- -------- --------- Underlying Operating Profit 4,915 5,178 (5.1%) -------- -------- --------- Underlying EBITDA 6,606 6,765 (2.4%) -------- -------- --------- Underlying EBITDA margin % 19.1% 18.7% 0.4% -------- -------- --------- Basic Underlying EPS (p) 5.9p 6.4p (7.8%) -------- -------- ---------
Revenue
Revenue for the period was GBP34.5m (2019: GBP36.1m) a decline of 4.4% (4.8% decline at CER). Revenue by product category is shown in the table below:
Six Months to 30 June 2020 2019 % Change at AER GBP'000 GBP'000 % -------- -------- --------- Companion Animals 21,210 23,724 (10.6%) -------- -------- --------- Production Animals 10,543 9,322 13.1% -------- -------- --------- Equine & other 2,767 3,075 (10.0%) -------- -------- --------- Total 34,520 36,121 (4.4%) -------- -------- ---------
Companion Animals revenue declined by 10.6% to GBP21.2m largely reflecting the disruption to veterinary activity across Europe caused by the pandemic. As we entered Q2, while the veterinary market remained open for business, in the majority of our markets, lock-down and social distancing measures led to restricted opening hours and consultations. This disruption has reduced the opportunities for interaction with many veterinary practices with the effect that launches of new products have been slowed or deferred.
The COVID-19 impact was particularly prevalent within the UK, which was subject to large-scale closures of veterinary practices, with all but urgent and emergency cases being seen. Together, these measures resulted in a marked decline in the number of clients visiting a small animal vet practice. Evidence of a return to more normal customer activity in some markets was visible at the end of the first half and has continued to develop post period-end. However, uncertainty about the shape and extent of a recovery in demand prevails.
In contrast, Production Animals revenue grew by 13.1% vs prior period to GBP10.5m, largely driven by strong growth in Spain, which benefited from the recent restructuring and partial reversal of the de-stocking observed towards the end of FY19. Large animal practices were in general less impacted due both to the requirement to protect the food chain and more industrial nature of this market. We expect this trend to continue through H2.
Equine and other sales decreased by 10.0% to GBP2.8m principally due to phasing of export sales.
Underlying operating results
Underlying EBITDA decreased by 2.4% to GBP6.6m (2019: GBP6.8m) principally reflecting the revenue decrease and higher percentage of lower margin Production Animals sales. However, Underlying EBITDA margin strengthened to 19.1% versus the prior period driven by the benefits from cost efficiencies generated during 2019 together with decisive action to realign SG&A spend during Q2. As a result, adjusted SG&A expenses as a percentage of revenue were 32.8% compared to 35.7%. Around half of the SG&A savings generated from deferred or contracted spend related to COVID-19 has been allocated to support continued investment in drivers of future growth including new product launches, pipeline projects and business development opportunities, which we expect to increase during the second half.
The underlying effective tax rate was 24.2% (2019: 20.9%) primarily reflecting the larger proportion of profits arising, and expected to arise, in higher rate tax jurisdictions. We continue to optimise research and development tax credits.
Reflecting the points noted above, underlying basic EPS decreased by 7.8% to 5.8 pence (2019: 6.4 pence).
Non-underlying items
Non-underlying items totalling GBP3.9m (2019: GBP6.7m) relating to profit before tax have been incurred in the period, as set out in note 3. These principally comprise:
1. Amortisation and impairment of acquisition related intangibles of GBP2.9m (2019: GBP4.5m). The decrease versus 2019 reflects the prior period non-cash impairment of three projects within the acquired product development pipeline at a fair value of GBP1.5m that failed to meet technical, competitive or commercial milestones.
2. Restructuring, acquisition and integration costs of GBP0.7m (2019: GBP1.9m) largely relating to restructuring of the Production Animals business unit in Spain and manufacturing transfer costs as we work towards simplifying our supply chain. The prior period charge primarily relates to the R&D and Technical & Regulatory team centralisation and associated costs of implementing headcount reduction.
Dividend
On 25 March 2020, the Group announced the deferral of its final dividend for 2019, preserving cash of GBP1.4m, with the aim of supporting our financial strength and providing a platform to continue progressing opportunities during the global COVID-19 pandemic. We noted that the decision would be reviewed later in the financial year once we had more clarity about the ongoing effects of the pandemic on our business, at which time any decision will consider what actions are in the best interest of long-term shareholder value.
After this review, the Board has decided to waive the final dividend for 2019 and re-allocate the GBP1.4m cash preserved to invest in growth. A proportion of these funds will be directed to support investment in the recently announced agreement with Kane Biotech.
In respect of the interim dividend, and reflecting the resilient first half trading performance, strong financial position and our more confident outlook, we are pleased to announce an interim dividend of 2.0 pence per share, in line with the prior period. The interim dividend will be paid on 20 November 2020 to shareholders whose names are on the Register of Members at close of business on 23 October 2020. The ordinary shares will become ex-dividend on 22 October 2020.
We strongly believe the above decisions are in the long-term interest of our stakeholders.
Cash flow, net debt and borrowing facilities
Establishing and maintaining a strong financial platform is at the core of our strategy. The Group remains committed to generating strong levels of operating cash and maintaining a solid balance sheet, important in providing capacity to invest in our business for growth.
Six months Six months to 30 June to 30 June 2020 2019 GBP'000 GBP'000 ------------------------------- ------------ ------------ Underlying EBITDA 6,606 6,765 ------------ ------------ Net cash flow from operations 3,076 4,831 ------------ ------------ Non-underlying items 686 1,415 ------------ ------------ Underlying net cash flow from operations 3,762 6,246 ------------ ------------ Cash conversion % 56.9% 92.3% ------------------------------- ------------ ------------
The Group's underlying cash conversion at 56.9% (2019: 92.3%) was impacted by a GBP3.7m increase in working capital compared to GBP1.0m in the prior period, largely reflecting movement in our inventories since the start of the financial year. Within our 2019 full year results announcement on 28 May 2020, we highlighted that, following the GBP2.5m reduction in FY19, we expected to increase inventories by approximately GBP1.5m during 2020 due to strategic stock build, relating to manufacturing transfers, in certain key brands. At the half year, such stock build equated to approximately GBP1.1m of the overall GBP2.3m cash increase in our inventories. The balance primarily relates to the demand disruption in Q2 trading as a result of COVID-19. During the second half we plan to invest a further GBP0.9m in stock cover for a Top 5 brand to protect sales in FY21.
Non-underlying cash items principally relate to the restructuring costs and post-acquisition and integration costs as noted above. Net debt has increased in the period by GBP0.3m to GBP18.1m. Exchange rate variations adversely impacted the net debt position by GBP1.7m.
GBP'000 Net debt at 1 January 2020 (17,812) --------- Net cash flow from operations 3,076 --------- Net capital expenditure (961) --------- Net finance expenses (845) --------- Foreign exchange on cash and borrowings (1,666) --------- Movement in IFRS16 lease liabilities 109 --------- Net debt at 30 June 2020 (18,099) ---------
During the period, all non-essential capex was put on hold, in effect preserving GBP0.4m. Net capital expenditure of GBP1.0m largely comprises investment in our novel pain product developed internally for use in dogs. This was submitted to the European Regulatory authority in January 2020 and the regulatory process is progressing in line with expectations. Subject to regulatory approval, we remain on track to launch during 2021.
The net debt to underlying EBITDA leverage ratio was 1.4 times (2019: 1.9 times) versus the bank covenant of 3.5 times. At 30 June 2020, total facilities were GBP47.0m, of which GBP18.5m, net of cash balances of GBP3.3m, was utilised, leaving headroom of GBP26.8m.
Going Concern
Banking Facilities and Covenants
At 30 June 2020, the Group's financing arrangements consisted of a committed revolving credit facility of EUR41.5m, a EUR10m acquisition line, which cannot be utilised to fund our operations, and EUR4.1m investment loans. All facilities mature in March 2022.
The facilities are subject to the following covenants which are in operation at all times:
-- Net debt to underlying EBITDA ratio of 3.5 times -- Underlying EBITDA to interest ratio of minimum 4 times -- Solvency (total assets less goodwill/total equity less goodwill) greater than 25%
As at 30 June 2020, all covenant requirements were met with significant headroom across all three measures. As at 30 August 2020, the net debt to underlying EBITDA ratio was approximately 1.2 times. Headroom on the banking facilities, including cash on balance sheet, was GBP28.1m.
COVID-19 Scenario Analysis - Update
The Group entered the pandemic period in a strong financial position, which has been maintained post period end, supported by careful management of both our SG&A costs and capital expenditure.
In our full year results announced on 28 May 2020, we shared a scenario analysis, attempting to quantify the potential impact on our business through to June 2021 of a range of downside revenue estimates with mitigating actions on cost and cash flow. At that time, we modelled a rolling 12-month downturn of between 13% and 22% compared to 2019, with the most significant impact during a quarter in which lockdown measures are enforced. In the downside scenarios, a prolonged lockdown of six months, or a second wave mirroring Q2 2020, both with subsequent slower recovery, was considered.
While trading for the first half was down on the prior period, our overall performance during Q2 was above the higher end of the Company's range of scenario modelling, leading to, as noted previously, a resilient first half year.
We have continued to develop and update our scenario analysis as the financial year progresses. Evidence of a return to more normal customer activity in some markets was visible at the end of the first half and has continued to develop post period-end. Uncertainty about the shape and extent of a recovery in demand prevails. However, we have demonstrated that the Group can and will take swift mitigating actions to maintain our financial resilience, including reducing SG&A spend, stopping all non-essential and non-committed capital expenditure and deferring dividends to preserve cash.
The results of these scenarios indicate that the Group would operate well within its committed revolving credit facility of EUR41.5m and maintain headroom against all covenant obligations for at least the next 12 months. Therefore, the Directors have a reasonable expectation that the Group will have sufficient cash flow and available resources to continue operating for at least 12 months from the approval date of the Interim Report. Accordingly, the Directors continue to adopt the going concern basis of preparation.
Summary and Outlook
Despite the unprecedented trading conditions caused by COVID-19, Animalcare has responded well to the challenge with a robust performance over the first half. The Group entered 2020 in a strong financial position, helping to protect Animalcare from the worst effects of the pandemic while continuing to make progress against strategic priorities.
The long-term fundamentals of the animal health market remain attractive: companion animal ownership and willingness to spend on treatment and wellbeing are increasing globally and demand for animal protein is growing. In the more immediate future, our customer base is showing continued signs of recovery post period as veterinary practices find ways to operate successfully in a world with COVID-19; in terms of revenue, for the eight months to the end of August, we traded broadly in line with the previous year.
Strategically, the Group continues to deliver on its growth ambitions with the post-period end agreement with Canadian company Kane Biotech to jointly target biofilm-related ailments in animals. Launches by Animalcare of Kane Biotech's oral care products outside the Americas are planned for the second half of 2021 and the Board expects the agreement to be earnings enhancing in 2022.
The Board acknowledges that a significant level of market and economic uncertainty remains, predominately due to COVID-19. Marked variations between different countries and factors such as the slower uptake of new products caused by disruption to the operation of veterinary practices make it difficult to forecast performance with any precision.
But whatever challenges the remainder of 2020 present, we are confident that the Group's strong finances, its proven agility and focus on a clear growth strategy mean Animalcare will continue to be well placed to take advantage of opportunities and generate long-term value for our shareholders.
Jenny Winter, Chief Executive Officer
Chris Brewster, Chief Financial Officer
Condensed consolidated income statement
For the six months ended 30 June -------------------------------------------------------------------------- Non-Underlying Non-Underlying Underlying (note 3) Total Underlying (note 3) Total ---------- -------------- -------- ---------- -------------- -------- Note 2020 2020 2020 2019 2019 2019 ---------- -------------- -------- ---------- -------------- -------- GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 Revenue 4 34,520 - 34,520 36,121 - 36,121 Cost of sales (16,583) - (16,583) (16,986) - (16,986) ---------- -------------- -------- ---------- -------------- --------
Gross profit 17,937 - 17,937 19,135 - 19,135 ---------- -------------- -------- ---------- -------------- -------- Research and development expenses (1,163) (547) (1,710) (1,662) (622) (2,284) Selling and marketing expenses (5,685) - (5,685) (6,222) - (6,222) General and administrative expenses (6,235) (2,376) (8,611) (6,109) (2,380) (8,489) Net other operating income / (expenses) 61 (986) (925) 36 (3,711) (3,675) ---------- -------------- -------- ---------- -------------- -------- Operating profit/(loss) 4 4,915 (3,909) 1,006 5,178 (6,713) (1,535) ---------- -------------- -------- ---------- -------------- -------- Financial expenses (488) - (488) (515) - (515) Financial income 244 - 244 216 - 216 Profit/(loss) before tax 4,671 (3,909) 763 4,879 (6,713) (1,834) ---------- -------------- -------- ---------- -------------- -------- Income tax (1,129) 832 (297) (1,022) 1,268 246 ---------- -------------- -------- ---------- -------------- -------- Net Profit/(loss) 4 3,542 (3,077) 466 3,857 (5,445) (1,588) ---------- -------------- -------- ---------- -------------- -------- Net profit/(loss) attributable to: ---------- -------------- -------- ---------- -------------- -------- The owners of the parent 3,542 (3,077) 466 3,857 (5,445) (1,588) ---------- -------------- -------- ---------- -------------- -------- Earnings per share for profit/(loss) attributable to the ordinary equity holders of the company: Basic 5.9p 0.8p 6.4p (2.6p) Diluted 5.9p 0.8p 6.4p (2.6p)
In order to aid understanding of underlying business performance, the Directors have presented underlying results before the effect of exceptional and other items. These exceptional and other items are analysed in note 3.
Condensed consolidated statement of comprehensive income
For the six months ended 30 June -------------------- 2020 2019 --------- --------- GBP'000 GBP'000 Net profit/(loss) for the period 466 (1,588) Other comprehensive income/(expense) Cumulative translation differences * 672 (90) --------- --------- Other comprehensive income/(expense), net of tax 672 (90) --------- --------- Total comprehensive income/(expense) for the period, net of tax 1,138 (1,678) ========= ========= Total comprehensive income/(expense) attributable to: The owners of the parent 1,138 (1,678) ========= ========= * May be reclassified subsequently to profit & loss
Condensed consolidated statement of financial position
30 June 30 June 31 December 2020 2019 2019 unaudited unaudited audited ---------- ---------- ----------- GBP'000 GBP'000 GBP'000 Assets Non-current assets Goodwill 51,135 50,940 50,454 Intangible assets 41,097 47,085 43,000 Property, plant and equipment 292 403 312 Right-of-use assets 1,805 2,194 1,917 Deferred tax assets 1,544 1,925 1,524 Other financial assets 63 60 59 Other non-current assets 49 291 72 Total non-current assets 95,985 102,898 97,338 ---------- ---------- ----------- Current assets Inventories 13,826 12,895 11,102 Trade receivables 11,852 12,046 10,891 Other current assets 1,032 3,230 2,746 Cash and cash equivalents 3,342 3,887 6,165 Total current assets 30,052 32,058 30,904 ---------- ---------- ----------- Total assets 126,037 134,956 128,242 ---------- ---------- ----------- Liabilities Current liabilities Borrowings (328) (324) (612) Lease liabilities (874) (938) (830) Trade payables (10,355) (9,581) (10,334) Tax payables (686) (1,896) (1,288) Accrued charges and deferred income (2,707) (2,299) (2,063) Other current liabilities (2,021) (3,371) (2,799) Total current liabilities (16,971) (18,409) (17,926) ---------- ---------- ----------- Non-current liabilities Borrowings (19,286) (24,477) (21,428) Lease liabilities (952) (1,276) (1,106) Deferred tax liabilities (5,028) (5,154) (5,176) Deferred income (600) (606) (599) Provisions (128) (106) (118) Total non-current liabilities (25,994) (31,619) (28,427) ---------- ---------- ----------- Total Liabilities (42,965) (50,028) (46,353) ---------- ---------- ----------- Net Assets 83,072 84,929 81,889 ========== ========== =========== Equity Share capital 12,012 12,012 12,012 Share premium 132,729 132,729 132,729 Reverse acquisition reserve (56,762) (56,762) (56,762) Accumulated losses (8,130) (6,305) (8,640) Other reserves 3,223 3,255 2,550 Equity attributable to the owners of the parent 83,072 84,929 81,889 ---------- ---------- ----------- Total equity 83,072 84,929 81,889 ========== ========== ===========
Condensed consolidated statement of changes in equity
Attributable to the owners of the parents ------------------------------------------------------------ Reverse Non- Share Share Accumulated acquisition Other controlling Total capital premium losses reserve reserve Total interest equity ------- ------- ----------- ----------- ------- ------- ----------- ------- GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 At 1 January 2019 12,012 132,729 (4,732) (56,762) 3,345 86,592 - 86,592 Net profit - - (1,588) - - (1,588) - (1,588) Other comprehensive expense - - - - (90) (90) - (90) Total comprehensive income/(expense) - - (1,588) - (90) (1,678) - (1,678) ------- ------- ----------- ----------- ------- ------- ----------- ------- Share-based payments - - 16 - - 16 - 16 At 30 June 2019 12,012 132,729 (6,305) (56,762) 3,255 84,929 - 84,929 ======= ======= =========== =========== ======= ======= =========== ======= Attributable to the owners of the parents ------------------------------------------------------------ Reverse Non- Share Share Accumulated acquisition Other controlling Total capital premium losses reserve reserve Total interest equity ------- ------- ----------- ----------- ------- ------- ----------- ------- GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 At 1 January 2020 12,012 132,729 (8,640) (56,762) 2,550 81,889 - 81,889 Net loss - - 466 - - 466 - - Other comprehensive expense - - - - 672 672 - 672 Total comprehensive expense - - 466 - 672 1,138 - 1,138 ------- ------- ----------- ----------- ------- ------- ----------- ------- Share-based payments - - 43 - - 43 - 43 At 30 June 2020 12,012 132,729 (8,130) (56,762) 3,223 83,072 - 83,072 ======= ======= =========== =========== ======= ======= =========== =======
Condensed consolidated cash flow statements
For the six months ended 30 June -------------------- 2020 2019 --------- --------- GBP'000 GBP'000 Cash flows from operating activities Profit/(loss) before tax 763 (1,834) Profit/(loss) before tax 763 (1,834) --------- --------- Adjustments for: Depreciation of property, plant and equipment 610 618 Amortisation of intangible assets 4,020 3,968 Impairment of intangible assets - 1,518 Share-based payment expense 43 16 Loss/(gain) on disposal of property, plant and equipment (16) - Non-cash movement in provisions 300 - Movement in allowance for bad debt and inventories 362 433 Financial income (148) (72) Financial expense 467 409 Impact of foreign currencies (79) (46) Non-cash restructuring expenses - 778 Other (3) (2) Movements in working capital (Increase)/decrease in trade receivables (582) 1,550 (Increase)/decrease in inventories (2,342) 1,533 Decrease in payables (797) (4,071) Income tax received 478 33 Net cash flow from operating activities 3,076 4,831 --------- --------- Investing activities Purchase of property, plant and equipment (49) (29) Purchase of intangible assets (961) (1,294) Proceeds from the sale of property, plant and equipment (net) 49 11 Net cash flow used in investing activities (961) (1,312) -------- -------- Financing activities Repayment of loans and borrowings (3,760) (6,508) Repayment IFRS16 lease liability (526) (491) Interest paid (264) (327) Other financial (expense)/income (55) (11) Net cash flow used in financing activities (4,605) (7,337) -------- -------- Net decrease in cash and cash equivalents (2,490) (3,819) ======== ======== Cash and cash equivalents at beginning of period 6,165 8,035 Exchange rate differences on cash and cash equivalents (333) (329) Cash and cash equivalents at end of period 3,342 3,887 ======== ======== Reconciliation of net cash flow to movement in net debt Net decrease in cash and cash equivalents in the period (2,490) (3,819) Cash flow from decrease in debt financing 3,760 6,508 Foreign exchange differences on cash and borrowings (1,666) (14) Movement in net debt in the period (396) 2,675 -------- -------- Net debt at the start of the period (17,812) (23,588) Movement in lease liabilities during the period 109 (2,214) Net debt at the end of the period (18,099) (23,127) ======== ========
Notes to the consolidated interim report
1 General information
Animalcare Group plc ("Animalcare" or "the Company") is a public company incorporated in England and Wales under the Companies Act 2006 and is domiciled in the United Kingdom. The condensed set of financial statements as at, and for, the six months ended 30 June 2020 comprises the Company and its subsidiaries (together referred to as the "Group"). The nature of the Group's operations and its principal activities are set out in the latest Annual Report.
2 Basis of preparation and significant accounting policies
This interim financial information for each of the six month periods ended 30 June 2020 and 30 June 2019 has not been audited and does not constitute statutory accounts as defined in Section 43s of the Companies Act 2006. The comparative information for the year ended 31 December 2019 does not constitute statutory accounts however is based on the statutory accounts for that year, on which the Group's auditors issued an unqualified report and which have been filed with the Register of Companies.
The Interim Report for the six months ended 30 June 2020 was approved by the Board of Directors and authorised for issue on 29 September 2020 .
Except as described below, the condensed consolidated interim financial information for the six months ended 30 June 2020 has been prepared using accounting policies consistent with those of the Company's annual accounts for the year ended 31 December 2019 which were prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union ("adopted IFRSs") and the amendment to IFRS 16 - Covid -19-related rent concessions , which will form the basis of the 2020 Annual Report.
Taxes on income in the interim periods are accrued using the estimated tax rate that would be applicable for the full financial year.
Several amendments and interpretations apply for the first time in 2020, but do not have an impact on the Interim Report of the Company:
- Amendments to References to the Conceptual Framework in IFRS Standards - IFRS 3 Business Combinations - Amendments to clarify the definition of a business - IAS 1 Presentation of Financial Statements - Amendments regarding the definition of material
- IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors - Amendments regarding the definition of material
- IFRS 9, IAS 39 and IFRS 7 - Amendments regarding the Interest Rate Benchmark Reform - IFRS 16 amendment - Covid-19-related rent concessions.
Going Concern
Banking Facilities and Covenants
At 30 June 2020, the Group's financing arrangements consisted of a committed revolving credit facility of EUR41.5m, a EUR10m acquisition line, which cannot be utilised to fund our operations, and EUR4.1m investment loans. All facilities mature in March 2022.
The facilities are subject to the following covenants which are in operation at all times:
-- Net debt to underlying EBITDA ratio of 3.5 times -- Underlying EBITDA to interest ratio of minimum 4 times -- Solvency (total assets less goodwill/total equity less goodwill) greater than 25%
As at 30 June 2020, all covenant requirements were met with significant headroom across all three measures.
As at 30 August 2020, the net debt to underlying EBITDA ratio was approximately 1.2 times. Headroom on the banking facilities, including cash on balance sheet, was GBP28.1m.
COVID-19 Scenario Analysis - Update
The Group entered the pandemic period in a strong financial position, which has been maintained post period end, supported by careful management of both our SG&A costs and capital expenditure.
In our full year results announced on 28 May 2020, we shared a scenario analysis, attempting to quantify the potential impact on our business through to June 2021 of a range of downside revenue estimates with mitigating actions on cost and cash flow. At that time, we modelled a rolling 12-month downturn of between 13% and 22% compared to 2019, with the most significant impact during a quarter in which lockdown measures are enforced. In the downside scenarios, a prolonged lockdown of six months, or a second wave mirroring Q2 2020, both with subsequent slower recovery, was considered.
While trading for the first half was down on the prior period, our overall performance during Q2 was above the higher end of the Company's range of scenario modelling, leading to, as noted previously, a resilient first half year.
We have continued to develop and update our scenario analysis as the financial year progresses. Evidence of a return to more normal customer activity in some markets was visible at the end of the first half and has continued to develop post period-end. Uncertainty about the shape and extent of a recovery in demand prevails. However, we have demonstrated that the Group can and will take swift mitigating actions to maintain our financial resilience, including reducing SG&A spend, stopping all non-essential and non-committed capital expenditure and deferring dividends to preserve cash.
The results of these scenarios indicate that the Group would operate well within its committed revolving credit facility of EUR41.5m and maintain headroom against all covenant obligations for at least the next 12 months. Therefore, the Directors have a reasonable expectation that the Group will have sufficient cash flow and available resources to continue operating for at least 12 months from the approval date of the Interim Report. Accordingly, the Directors continue to adopt the going concern basis of preparation.
3 Non-underlying items For the six months ended 30 June -------------------- 2020 2019 --------- --------- GBP'000 GBP'000 Amortisation and impairment of acquisition related intangibles Classified within Research and development expenses 547 622 Classified within General and administrative expenses 2,376 2,380 Classified within net other operating expenses - 1,518 Total amortisation and impairment of acquisition related intangibles 2,923 4,520 --------- --------- Restructuring costs 351 1,823 Acquisition and integration costs 304 77 Divestments and business disposals 49 - Brexit-related costs 2 118 Other non-underlying items 280 175 Total non-underlying items before taxes 3,909 6,713 --------- --------- Tax impact (832) (1,268) Total non-underlying items after taxes 3,077 5,445 ========= =========
The amortisation charge of acquisition related intangibles largely relates to the Esteve acquisition GBP1,001k (30 June 2019 : GBP1,005k) and the reverse acquisition of Animalcare Group plc GBP1,740k (30 June 2019 : GBP1,814k).
Restructuring, acquisition and integration costs of GBP0.7m (2019: GBP1.9m) largely relating to restructuring of the Production Animals business unit in Spain and manufacturing transfer costs as we work towards simplifying our supply chain. The prior period charge primarily relates to the R&D and Technical & Regulatory team centralisation and associated costs of implementing headcount reduction.
In 2019, the Group recorded an impairment charge of GBP1,518k for acquisition related intangibles that related to an impairment of projects within the R&D pipeline who are deemed no longer economically viable due to technical difficulties in the development process.
4 Segment information
The Group reports one business segment, being "Pharmaceuticals". This reporting segment is used for management purposes. The Pharmaceutical segment is active in the development and marketing of innovative pharmaceutical products that provide significant benefits to animal health.
The measurement principles used by the Group in preparing this segment reporting are also the basis for segment performance assessment. The Board of Directors of the Group acts as the Chief Operating Decision Maker. The Chief Operating Decision Maker assesses performance based on the Key Performance Indicators set out on page 14 of the latest Annual Report which include revenue and underlying EBITDA, excluding the effect of non-underlying items.
The following table shows an analysis of the segment reporting from continuing operations. As management's controlling instrument is mainly revenue-based, the reporting information does not include assets and liabilities by segment and is as such not presented per segment.
For the six months ended 30 June ---------------- 2020 2019 ------- ------- Pharma Pharma ------- ------- GBP'000 GBP'000 Revenues 34,520 36,121 Gross Margin 17,936 19,135 Gross Margin % 52.0% 53.0% Segment underlying EBITDA 6,606 6,765 Segment underlying EBITDA % 19.1% 18.7% Segment EBITDA 5,634 4,573 Segment EBITDA % 16.3% 12.7%
The segment EBITDA is reconciled with the consolidated net profit of the year as follows:
For the six months ended 30 June -------------------- 2020 2019 --------- --------- GBP'000 GBP'000 Segment EBITDA 5,634 4,573 Depreciation, amortisation and impairment (4,628) (6,108) Operating profit/(loss) 1,006 (1,535) --------- --------- Financial expenses (488) (515) Financial income 244 216 Income taxes (402) (346) Deferred taxes 106 592 Net profit/(loss) 466 (1,588)
========= =========
Revenue by product category:
For the six months ended 30 June ---------------- 2020 2019 ------- ------- GBP'000 GBP'000 Companion animals 21,210 23,724 Production animals 10,543 9,322 Equine 2,758 2,970 Pet food, Instrumentation and Services - 105 Total 34,520 36,121 ======= =======
Revenue by geographical area:
For the six months ended 30 June ---------------- 2020 2019 ------- ------- GBP'000 GBP'000 Belgium 4,840 4,351 The Netherlands 659 1,090 United Kingdom 4,255 7,211 Germany 5,209 5,081 Spain 9,650 9,771 Italy 3,895 2,857 Portugal 2,379 2,575 European Union - other 2,608 2,612 Asia 603 238 Middle East Africa 26 23 Other 396 312 Total 34,520 36,121 ======= =======
Revenue by category:
For the six months ended 30 June ---------------- 2020 2019 ------- ------- GBP'000 GBP'000 Product sales 34,000 35,551 Services sales 520 570 Total 34,520 36,121 ======= =======
Product revenue is recognised when the performance obligation is satisfied at a point in time. Service revenue is recognised by reference to the stage of completion.
5 Earnings per share
Basic earnings per share amounts are calculated by dividing the net profit for the period attributable to ordinary equity holders of the parent company by the weighted average number of ordinary shares outstanding during the year.
Diluted earnings per share amounts are calculated by dividing the net profit attributable to ordinary equity holder of the parent company by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all potential dilutive ordinary shares.
The following income and share data were used in the earnings per share computations:
For the six months ended 30 June ------------------------------- ------- Underlying Underlying Total Total ---------- ---------- ------- ------- 2020 2019 2020 2019 ---------- ---------- ------- ------- GBP'000 GBP'000 GBP'000 GBP'000 Net profit/(loss) 3,542 3,857 466 (1,588) Net profit/(loss) attributable to ordinary equity holders of the parent adjusted for the effect of dilution 3,542 3,857 466 (1,588) ========== ========== ======= =======
Average number of shares (basic and diluted):
For the six months ended 30 June ------------------------------------ ------------ Underlying Underlying Total Total ---------- ------------ ---------- ------------ 2020 2019 2020 2019 ---------- ------------ ---------- ------------ Number Number Number Number Weighted average number of ordinary shares for basic earnings per share 60,057,161 60,057,161 60,057,161 60,057,161 Dilutive potential ordinary shares 256,510 - 256,510 - Weighted average number of ordinary shares adjusted for effect of dilution 60,313,671 60,057,161 60,313,671 60,057,161 ========== ============ ========== ============
Basic earnings/(loss) per share:
For the six months ended 30 June ------------------------------- ----- Underlying Underlying Total Total ----------- ----------- ----- ----- 2020 2019 2020 2019 ----------- ----------- ----- ----- Pence Pence Pence Pence Basic earnings/(loss) per share attributable to the ordinary equity holders of the company 5.9 6.4 0.8 (2.6) =========== =========== ===== =====
Diluted earnings/(loss) per share:
For the six months ended 30 June ------------------------------- ----- Underlying Underlying Total Total ----------- ----------- ----- ----- 2020 2019 2020 2019 ----------- ----------- ----- ----- Pence Pence Pence Pence Diluted earnings/(loss) per share attributable to the ordinary equity holders of the company 5.9 6.4 0.8 (2.6) =========== =========== ===== ===== 6 Dividends
On 25 March 2020, the Group announced the deferral of its final dividend for 2019, preserving cash of GBP1.4m, with the aim of supporting our financial strength and providing a platform to continue progressing opportunities during the global COVID-19 pandemic. We noted that the decision would be reviewed later in the financial year once we had more clarity about the ongoing effects of the pandemic on our business, at which time any decision will consider what actions are in the best interest of long-term shareholder value.
After this review, the Board has decided to waive the final dividend for 2019 and re-allocate the GBP1.4m cash preserved to invest in growth.
In respect of the interim dividend, and reflecting the resilient first half trading performance, strong financial position and our more confident outlook, we are pleased to announce an interim dividend of 2.0 pence per share, in line with the prior period. The interim dividend will be paid on 20 November 2020 to shareholders whose names are on the Register of Members at close of business on 23 October 2020. The ordinary shares will become ex-dividend on 22 October 2020.
We strongly believe the above decisions are in the long-term interest of our stakeholders.
As the dividend was declared after the end of the period being reported, it has not been included as a liability as at 30 June 2020 in accordance with IAS 10 'Events after the Balance Sheet date'.
7 Contingent Liabilities
On 3 September 2018, Ecuphar NV sold the wholesale business Medini NV to Vetdis Holding NV under a Share Purchase Agreement (SPA). In June 2019, Vetdis sent a letter to Ecuphar claiming that Ecuphar had breached the SPA. Ecuphar disputed the basis and the value of the claim. Following various discussions and correspondence, during which the parties have been unable to reach any agreement, Vetdis issued formal court papers on 29 May 2020. A preliminary court hearing took place on 3 September 2020 and a procedural calendar has been set by the court up to 31 January 2021 to submit legal briefs. The Company strongly disagrees with the claim and has not made any provision in respect of this matter in the financial statements. As part of our defence we have counter-claimed for the outstanding amounts due to Ecuphar under the SPA.
8 Related part transactions
There have been no new related party transactions that have taken place in the six months ended 30 June 2020 .
9 Subsequent events
On 28 September 2020 the Group announced that it has entered into an agreement with Canada-based biotech company Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) under which the parties will form STEM Animal Health Inc. ("STEM"), a company dedicated to treating biofilm-related ailments in animals. Animalcare will invest CA$5 million, consisting of CA$3 million to acquire a one-third stake in STEM, and a further CA$2 million for rights to commercialise products in global veterinary markets outside of the Americas.
10 Cautionary statement
This Interim Management Report ("IMR") consists of the Chairman's Statement and the Business Review, which have been prepared solely to provide additional information to shareholders to assess the Group's strategies and the potential for those strategies to succeed. The IMR should not be relied upon by any other party or for any other purpose.
The IMR contains a number of forward-looking statements. These statements are made by the Directors in good faith based upon the information available to them up to the time of their approval of this report and such statements should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying any such forward looking information.
This IMR has been prepared for the Group as a whole and therefore emphasises those matters which are significant to Animalcare Group plc and its subsidiaries when viewed as a whole.
11 Interim report
The Group's Interim Report for the six months ended 30 June 2020 was approved and authorised for issue on 29 September 2020 . Copies will be available to download on the Company's website at: www.animalcaregroup.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR SEIEEAESSEFU
(END) Dow Jones Newswires
September 29, 2020 02:00 ET (06:00 GMT)
1 Year Animalcare Chart |
1 Month Animalcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions